Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile.

Dubbelboer IR, Pavlovic N, Heindryckx F, Sjögren E, Lennernäs H.

Cancers (Basel). 2019 Jul 20;11(7). pii: E1024. doi: 10.3390/cancers11071024.

2.

Platelets as Key Factors in Hepatocellular Carcinoma.

Pavlovic N, Rani B, Gerwins P, Heindryckx F.

Cancers (Basel). 2019 Jul 20;11(7). pii: E1022. doi: 10.3390/cancers11071022. Review.

3.

Role of proteoglycans in neuro-inflammation and central nervous system fibrosis.

Heindryckx F, Li JP.

Matrix Biol. 2018 Aug;68-69:589-601. doi: 10.1016/j.matbio.2018.01.015. Epub 2018 Jan 31. Review.

PMID:
29382609
4.

Macrophage Depletion Attenuates Extracellular Matrix Deposition and Ductular Reaction in a Mouse Model of Chronic Cholangiopathies.

Best J, Verhulst S, Syn WK, Lagaisse K, van Hul N, Heindryckx F, Sowa JP, Peeters L, Van Vlierberghe H, Leclercq IA, Canbay A, Dollé L, van Grunsven LA.

PLoS One. 2016 Sep 12;11(9):e0162286. doi: 10.1371/journal.pone.0162286. eCollection 2016.

5.

Endoplasmic reticulum stress enhances fibrosis through IRE1α-mediated degradation of miR-150 and XBP-1 splicing.

Heindryckx F, Binet F, Ponticos M, Rombouts K, Lau J, Kreuger J, Gerwins P.

EMBO Mol Med. 2016 Jul 1;8(7):729-44. doi: 10.15252/emmm.201505925. Print 2016 Jul.

6.

Time-dependent effect of hypoxia on tumor progression and liver progenitor cell markers in primary liver tumors.

Bogaerts E, Heindryckx F, Devisscher L, Paridaens A, Vandewynckel YP, Van den Bussche A, Verhelst X, Libbrecht L, van Grunsven LA, Geerts A, Van Vlierberghe H.

PLoS One. 2015 Mar 20;10(3):e0119555. doi: 10.1371/journal.pone.0119555. eCollection 2015.

7.

Targeting the tumor stroma in hepatocellular carcinoma.

Heindryckx F, Gerwins P.

World J Hepatol. 2015 Feb 27;7(2):165-76. doi: 10.4254/wjh.v7.i2.165. Review.

8.

Hepatitis mouse models: from acute-to-chronic autoimmune hepatitis.

Yüksel M, Laukens D, Heindryckx F, Van Vlierberghe H, Geerts A, Wong FS, Wen L, Colle I.

Int J Exp Pathol. 2014 Oct;95(5):309-20. doi: 10.1111/iep.12090. Epub 2014 Aug 12. Review.

9.

The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review).

Bogaerts E, Heindryckx F, Vandewynckel YP, Van Grunsven LA, Van Vlierberghe H.

Int J Oncol. 2014 Apr;44(4):1015-22. doi: 10.3892/ijo.2014.2286. Epub 2014 Feb 3. Review.

10.

The paradox of the unfolded protein response in cancer.

Vandewynckel YP, Laukens D, Geerts A, Bogaerts E, Paridaens A, Verhelst X, Janssens S, Heindryckx F, Van Vlierberghe H.

Anticancer Res. 2013 Nov;33(11):4683-94. Review.

PMID:
24222102
11.

The need for transparency and good practices in the qPCR literature.

Bustin SA, Benes V, Garson J, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley G, Wittwer CT, Schjerling P, Day PJ, Abreu M, Aguado B, Beaulieu JF, Beckers A, Bogaert S, Browne JA, Carrasco-Ramiro F, Ceelen L, Ciborowski K, Cornillie P, Coulon S, Cuypers A, De Brouwer S, De Ceuninck L, De Craene J, De Naeyer H, De Spiegelaere W, Deckers K, Dheedene A, Durinck K, Ferreira-Teixeira M, Fieuw A, Gallup JM, Gonzalo-Flores S, Goossens K, Heindryckx F, Herring E, Hoenicka H, Icardi L, Jaggi R, Javad F, Karampelias M, Kibenge F, Kibenge M, Kumps C, Lambertz I, Lammens T, Markey A, Messiaen P, Mets E, Morais S, Mudarra-Rubio A, Nakiwala J, Nelis H, Olsvik PA, Pérez-Novo C, Plusquin M, Remans T, Rihani A, Rodrigues-Santos P, Rondou P, Sanders R, Schmidt-Bleek K, Skovgaard K, Smeets K, Tabera L, Toegel S, Van Acker T, Van den Broeck W, Van der Meulen J, Van Gele M, Van Peer G, Van Poucke M, Van Roy N, Vergult S, Wauman J, Tshuikina-Wiklander M, Willems E, Zaccara S, Zeka F, Vandesompele J.

Nat Methods. 2013 Nov;10(11):1063-7. doi: 10.1038/nmeth.2697.

PMID:
24173381
12.

MicroRNA-24 suppression of N-deacetylase/N-sulfotransferase-1 (NDST1) reduces endothelial cell responsiveness to vascular endothelial growth factor A (VEGFA).

Kasza Z, Fredlund Fuchs P, Tamm C, Eriksson AS, O'Callaghan P, Heindryckx F, Spillmann D, Larsson E, Le Jan S, Eriksson I, Gerwins P, Kjellén L, Kreuger J.

J Biol Chem. 2013 Sep 6;288(36):25956-63. doi: 10.1074/jbc.M113.484360. Epub 2013 Jul 24.

13.

Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models.

Coulon S, Legry V, Heindryckx F, Van Steenkiste C, Casteleyn C, Olievier K, Libbrecht L, Carmeliet P, Jonckx B, Stassen JM, Van Vlierberghe H, Leclercq I, Colle I, Geerts A.

Hepatology. 2013 May;57(5):1793-805. doi: 10.1002/hep.26219. Epub 2013 Mar 14.

PMID:
23299577
14.

The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model.

Heindryckx F, Coulon S, Terrie E, Casteleyn C, Stassen JM, Geerts A, Libbrecht L, Allemeersch J, Carmeliet P, Colle I, Van Vlierberghe H.

J Hepatol. 2013 Feb;58(2):319-28. doi: 10.1016/j.jhep.2012.09.032. Epub 2012 Oct 6.

PMID:
23046674
15.

Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor.

Blomme B, Heindryckx F, Stassen JM, Geerts A, Colle I, Van Vlierberghe H.

Mol Cell Biochem. 2013 Jan;372(1-2):199-210. doi: 10.1007/s11010-012-1461-1. Epub 2012 Sep 24.

PMID:
23001868
16.

New therapeutic targets in veterinary oncology: man and dog definitely are best friends.

Casteleyn C, Sleeckx N, De Spiegelaere W, Heindryckx F, Coulon S, Van Steenkiste C.

Vet J. 2013 Jan;195(1):6-7. doi: 10.1016/j.tvjl.2012.06.011. Epub 2012 Jul 13. No abstract available.

PMID:
22795959
17.

Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model.

Heindryckx F, Bogaerts E, Coulon SH, Devlies H, Geerts AM, Libbrecht L, Stassen JM, Carmeliet P, Colle IO, Van Vlierberghe HR.

Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1020-32. doi: 10.1097/MEG.0b013e3283554219.

PMID:
22772092
18.

Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease.

Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, De Munter S, Prawitt J, Caron S, Staels B, Van Vlierberghe H, Van Gaal L, Geerts A.

Cytokine. 2012 Aug;59(2):442-9. doi: 10.1016/j.cyto.2012.05.001. Epub 2012 May 31.

PMID:
22658783
19.

Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice.

Heindryckx F, Kuchnio A, Casteleyn C, Coulon S, Olievier K, Colle I, Geerts A, Libbrecht L, Carmeliet P, Van Vlierberghe H.

J Hepatol. 2012 Jul;57(1):61-8. doi: 10.1016/j.jhep.2012.02.021. Epub 2012 Mar 13.

PMID:
22420978
20.

Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice.

Van Steenkiste C, Ribera J, Geerts A, Pauta M, Tugues S, Casteleyn C, Libbrecht L, Olievier K, Schroyen B, Reynaert H, van Grunsven LA, Blomme B, Coulon S, Heindryckx F, De Vos M, Stassen JM, Vinckier S, Altamirano J, Bataller R, Carmeliet P, Van Vlierberghe H, Colle I, Morales-Ruiz M.

Hepatology. 2011 May;53(5):1629-40. doi: 10.1002/hep.24238.

PMID:
21520176
21.

Angiogenesis in chronic liver disease and its complications.

Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H.

Liver Int. 2011 Feb;31(2):146-62. doi: 10.1111/j.1478-3231.2010.02369.x. Epub 2010 Nov 15. Review.

PMID:
21073649
22.

Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma.

Heindryckx F, Mertens K, Charette N, Vandeghinste B, Casteleyn C, Van Steenkiste C, Slaets D, Libbrecht L, Staelens S, Starkel P, Geerts A, Colle I, Van Vlierberghe H.

Mol Cancer. 2010 Aug 20;9:219. doi: 10.1186/1476-4598-9-219.

23.

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.

Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, Van Steenkiste C, Tugues S, Rolny C, De Mol M, Dettori D, Hainaud P, Coenegrachts L, Contreres JO, Van Bergen T, Cuervo H, Xiao WH, Le Henaff C, Buysschaert I, Kharabi Masouleh B, Geerts A, Schomber T, Bonnin P, Lambert V, Haustraete J, Zacchigna S, Rakic JM, Jiménez W, Noël A, Giacca M, Colle I, Foidart JM, Tobelem G, Morales-Ruiz M, Vilar J, Maxwell P, Vinores SA, Carmeliet G, Dewerchin M, Claesson-Welsh L, Dupuy E, Van Vlierberghe H, Christofori G, Mazzone M, Detmar M, Collen D, Carmeliet P.

Cell. 2010 Apr 2;141(1):178-90. doi: 10.1016/j.cell.2010.02.039.

24.

Experimental mouse models for hepatocellular carcinoma research.

Heindryckx F, Colle I, Van Vlierberghe H.

Int J Exp Pathol. 2009 Aug;90(4):367-86. doi: 10.1111/j.1365-2613.2009.00656.x. Review.

Supplemental Content

Loading ...
Support Center